Advertisement

Management of Gastrinoma

  • Rachel E. Simpson
  • Benjamin C. JamesEmail author
Chapter

Abstract

Gastrinoma is a functioning neuroendocrine tumor resulting in the oversecretion of gastrin. Patients often present with abdominal pain, diarrhea, and reflux. They are most often sporadic but may be associated with multiple endocrine neoplasia type 1 (MEN1) in a minority of cases. Biochemical testing for hypergastrinemia includes a fasting serum gastrin level. If the results are equivocal, a secretin stimulation test can be performed. After the diagnosis is confirmed, cross-sectional imaging should be performed which will most often localize the tumor to the gastrinoma triangle. Further localization may include somatostatin receptor scintigraphy and endoscopic ultrasound. Medical treatment should be guided toward decreasing the burden of hypersecretion with either proton pump inhibitors or histamine-2 receptor blockers. For isolated, sporadic gastrinomas, treatment includes surgical resection. However, roughly 50% of patients with have metastatic disease at the time of diagnosis. The approach for patients with MEN1 is less clear.

Keywords

Zollinger-Ellison syndrome Peptic ulcer disease Multiple endocrine neoplasia 1 Hypergastrinemia Secretin-stimulation test Gastrinoma triangle Octreotide 

References

  1. 1.
    Townsend CM Jr, Beauchamp RD, Evers BM, Mattox KL. Chapter 38: Endocrine pancreas. In: Sabiston textbook of surgery. 20th ed. Philadelphia: Elsevier; 2017. p. 941–62.Google Scholar
  2. 2.
    Melmed S, Polonsky KS, Larsen PR, Kronenberg HM. Chapter 39: Multiple endocrine neoplasia. In: Williams textbook of endocrinology. 13th ed. Philadelphia: Elsevier; 2016. p. 1723–61.Google Scholar
  3. 3.
    Jameson JL, De Groot LJ, de Kretser DM, Giudice LC, Grossman AB, Melmed S, Potts JT, Weir GC. Chapter 148: Multiple endocrine neoplasia Type 1. In: Endocrinology: adult and pediatric. 7th ed. Elsevier Saunders: Philadelphia; 2016. p. 2566–93.Google Scholar
  4. 4.
    Feldman M, Friedman LS, Brandt LJ. Chapter 33: Neuroendocrine tumors. In: Sleisenger and Fordtran’s gastrointestinal and liver disease. 10th ed. Philadelphia: Elsevier; 2016. p. 501–41.Google Scholar
  5. 5.
    McPherson RA, Pincus MR. Chapter 22: Laboratory diagnosis of gastrointestinal and pancreatic disorders. In: Henry’s clinical diagnosis and management by laboratory methods. St. Louis: Elsevier; 2017. p. 306–23.Google Scholar
  6. 6.
    Lopez CL, Falconi M, Waldmann J, Boninsegna L, Fendrich V, Goretzki PK, Langer P, Kann PH, Partelli S, Bartsch DK. Partial pancreaticoduodenectomy can provide cure for duodenal gastrinoma associated with multiple endocrine neoplasia Type 1. Ann Surg. 2013;257(2):308–14.CrossRefGoogle Scholar
  7. 7.
    Tonelli F, Fratini G, Falchetti A, Nesi G, Brandi ML. Surgery for gastroenteropancreatic tumours in multiple endocrine neoplasia type 1: review and personal experience. J Intern Med. 2005;257(1):38–49.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of SurgeryIndiana UniversityIndianapolisUSA
  2. 2.Department of SurgeryHarvard Medical SchoolBostonUSA
  3. 3.Department of SurgeryBeth Israel Deaconess Medical CenterBostonUSA

Personalised recommendations